Tuesday, April 21, 2015 10:00:29 AM
http://www.hypersolar.com/news_detail.php?id=55
HYSR Extends Thru July 2014 -- In July Sponsorship is again extended
In the next phase of the research program with UCSB, the team aims to achieve the following milestones:
1. Fabricate solar absorbers using low cost methods
2. Build a low cost 1.5 volt prototype particle capable of direct water splitting
Tim Young, CEO of HyperSolar, said, "Our cutting-edge research program at the University of California Santa Barbara led by Dr. Syed Mubeen Hussaini continues to make impressive progress. The recently announced 1.1 volt milestone is very exciting in that it provides us with a clear and encouraging roadmap to reach the 1.5 volts needed for splitting water molecules into hydrogen and oxygen. We believe that producing renewable hydrogen anywhere there is water and sunlight is the key to realizing a sustainable hydrogen economy. For example, using our technology, hydrogen fueling stations could be built next to self-contained solar hydrogen production plants."
http://www.marketwired.com/press-release/hypersolar-extends-agreement-with-top-university-for-research-and-development-otcqb-hysr-1869181.htm
Recent HYSR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:09 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 01/25/2024 09:40:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2023 09:03:04 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/29/2023 08:33:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:13:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM